• Profile

Study finds how bacteria in the stomach ease constipation

ANI Nov 22, 2023

Researchers have determined which genes in the probiotic Bifidobacteria longum enhance intestinal motility. Researchers discovered that B. longum strains with the abfA cluster of genes can reduce constipation by improving the gut's utilisation of arabinan, an indigestible fibre.

Their findings were published in the journal Cell Host & Microbe.

"We established the causal link between a genetic variant--the abfA cluster--to the key functional difference of probiotic B. longum in multiple model organisms, including experimental models and humans, and provided mechanistic and ecological insights into how a single gene cluster can affect the gut motility of hosts through arabinan metabolism," said Qixiao Zhai of Jiangnan University, one of the paper's co-senior authors.

Impaired gastrointestinal motility has been implicated in gut microbial dysbiosis, which is characterised by a significant decrease in the abundance of beneficial microorganisms, some of which are conventionally known as probiotics. Orally administrated probiotics have therefore been widely used to alleviate symptoms.

Yet the therapeutic effect of probiotics for constipation often varies substantially across strains within the same species. Due to elusive mechanisms, the rational choice of probiotics remains challenging for medical care professionals and patients. In addition, most evidence on the beneficial effects of probiotics on gut motility mainly emerged from studies using an experimental model.

"Probiotic strains were often effective in experimental models yet failed in human clinical trials or were poorly validated in humans," said Jiachao Zhang of Hainan University, the study's second co-senior author.

"Proof-of-concept studies based on a human cohort in combination with evidence from experimental model studies are urgently needed for translational research."

Zhai, Zhang, and Shi Huang of the University of Hong Kong, the paper's third co-senior author, set out to identify and systematically validate the key genetic factors of exogenous probiotics or resident gut microbiota affecting gastrointestinal motility. They isolated 185 B. longum strains from 354 Chinese subjects who ranged in age from 0 to 108 years.

From a comprehensive library of wild B. longum strains, they discovered that the effective alleviation of constipation in the experimental model is regulated by the abfA cluster. This key genetic factor preferentially enhances the utilisation of arabinan--a common constituent of plant polysaccharides, an indigestible fibre for humans, and a poorly accessible source of nutrients for normal gut microbes.

The researchers further validated the abfA cluster's functional roles using gene-knockout experiments. In an experimental model with constipation, B. longum, but not an abfA mutant, improved gastrointestinal transit time--an effect that was dependent upon dietary arabinan.

To establish its functional roles for ameliorating constipation in humans, the researchers used a clinical trial and a human-to-experimental model faecal microbiota transplantation experiment in combination with metagenomics and metabolomics.

In the double-blind, randomised, placebo-controlled clinical trial, supplementation with abfA-cluster-carrying B. longum, but not an abfA-deficient strain, enriched arabinan-utilisation residents, increased beneficial metabolites, and improved constipation symptoms.

Across human cohorts, abfA-cluster abundance in the faecal microbiomes predicted constipation and transplantation of abfA cluster-enriched human microbiota to experimental model with constipation improved gut motility.

Notably, other than B. longum, the abfA gene/cluster is prevalent in gut residents, regulating symptoms in both experimental models and humans.

The authors say that the abfA cluster is a gut-microbiome therapeutic target for constipation in humans. More broadly, the results suggest that genetic factors governing the unique metabolic capability of probiotics should be primarily considered for screening probiotics or inferring their treatment efficacy for gastrointestinal diseases.

"Collectively, this study identified and systematically characterised a key genetic factor responsible for arabinan utilisation that addressed one critical challenge in the probiotic field, namely widespread yet unknown strain specificity in probiotic treatment efficacy," Huang said.

"Our proof-of-concept study also established generalisable principles for the rational development of colonisable, functional probiotics with persistent treatment efficacy in multiple model organisms. Moreover, the abfA cluster is so prevalent in the gut microbiota that it can be developed as a simple yet powerful biomarker for gastrointestinal diseases."

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen